Vyvgart Market Report 2026

Vyvgart Market Overview

• The Vyvgart market growth in the historic period has been driven by improved understanding of autoimmune disease mechanisms, approval of novel biologic therapies • Market expansion is supported by expansion of indications beyond gMG, growing adoption of precision immunology treatments • Growth Driver: Rising Prevalence Of Autoimmune Diseases Fueling Growth In The Market • Market Trend: Regulatory Approvals Driving Market Expansion And Competitive Edge • North America was the largest region in 2025.

What Is Covered Under Vyvgart Market?

Vyvgart (efgartigimod alfa-fcab) is a medication used to treat certain autoimmune diseases, particularly generalized myasthenia gravis (gMG), a rare condition that causes weakness in the skeletal muscles. It works by targeting and inhibiting the activity of the neonatal Fc receptor (FcRn), which helps reduce the levels of pathogenic antibodies that contribute to the disease's symptoms. By lowering these antibodies, vyvgart helps improve muscle strength and reduces disease-related fatigue. The main indications for vyvgart are generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). Generalized Myasthenia Gravis (gMG) is a chronic autoimmune neuromuscular disorder that causes muscle weakness by disrupting communication between nerves and muscles. The end users are adults and geriatrics and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Vyvgart Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of indications beyond gMG, growing adoption of precision immunology treatments, increasing investments in autoimmune biologics, rising demand for long-term disease control options, development of next-generation fcrn inhibitors. Major trends in the forecast period include expanding adoption of fcrn inhibitor therapies, rising focus on targeted autoimmune disease treatments, increasing clinical use of antibody reduction mechanisms, growing demand for personalized immunotherapy solutions, enhanced emphasis on long-term disease management.

What Is The Driver Of The Vyvgart Market?

The increasing prevalence of autoimmune diseases is expected to propel the growth of the vyvgat market going forward. Autoimmune diseases are conditions in which the body's immune system mistakenly attacks its own healthy cells and tissues, perceiving them as foreign or harmful. The rise in autoimmune diseases is largely attributed to a combination of genetic predisposition, environmental factors, infections, and changes in lifestyle, such as diet and increased exposure to chemicals. Vyvgart (efgartigimod alfa-fcab) is used to treat autoimmune diseases, specifically generalized myasthenia gravis (gMG), by targeting and inhibiting the neonatal Fc receptor (FcRn) from reducing pathogenic antibodies that contribute to the disease. For instance, in August 2024, according to the Myasthenia Gravis Foundation of America, a US-based organization, myasthenia gravis affects approximately 150 to 200 individuals per million people worldwide. In the United States, it is estimated that 37 out of every 100,000 people have the condition. Therefore, the increasing prevalence of autoimmune diseases is driving the vyvgat market.

Key Players In The Global Vyvgart Market

Major companies operating in the vyvgart market are Argenx SE

Global Vyvgart Market Trends and Insights

The key trend in the vyvgart market is the emphasis on obtaining regulatory approvals to gain a competitive edge. These approvals are crucial for validating the safety and efficacy of Vyvgart in treating autoimmune diseases. They enhance the drug's market accessibility and bolster confidence among physicians and patients. For instance, in March 2024, argenx, a Netherlands-based immunology company, announced that its innovative treatment, VYVGART (efgartigimod alfa), received approval in Japan for adults suffering from primary immune thrombocytopenia (ITP). This approval, granted by Japan’s Ministry of Health, Labour and Welfare, marks the first global endorsement of VYVGART specifically for ITP, expanding its therapeutic applications beyond generalized myasthenia gravis (gMG), for which it has already been approved in various regions, including the United States and Europe. VYVGART is a human IgG1 antibody fragment that targets the neonatal Fc receptor (FcRn), leading to a reduction in circulating IgG autoantibodies. This mechanism provides a new treatment option for patients who have been awaiting effective therapies for this autoimmune condition.

What Are Latest Mergers And Acquisitions In The Vyvgart Market?

In September 2025, FUJIFILM Holdings Corporation, a Japan-based contract development and manufacturing organization, partnered with argenx to expand its global manufacturing collaboration. This partnership aims to enhance argenx’s manufacturing capacity, strengthen its U.S. supply chain, and ensure reliable global access to its therapies. Argenx SE is a Netherlands-based immunology company that provides Vyvgart.

What Defines the Vyvgart Market?

The vyvgart market consists of sales of intravenous (IV) infusion. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vyvgart Market Report 2026?

The vyvgart market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vyvgart industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.